Michael Groessl

Cette personne n’est plus à l’EPFL

Publications associées (22)

À propos
Confidentialité
Mentions légales

Graph Chatbot

KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients

Paul Joseph Dyson, Christian Hartinger, Michael Groessl

A review. The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) is the second Ru-based anticancer agent to enter clin. trials. In this review, which is an update of a paper from 2006, the exptl. evidence for the ...

2008

In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands

Paul Joseph Dyson, Christian Hartinger, Alexey Nazarov, Olivier Pierre Zava, Michael Groessl, Frédéric Schmitt, Muhammad Hanif

The synthesis and in vitro anticancer activity of dihalo(η6-p-cymene)(3,5,6-bicyclophosphite-α-D-glucofuranoside)ruthenium(II) complexes are described. The compds. were characterized by NMR spectroscopy and ESI mass spectrometry, and the mol. structures of ...

2008

Page 3 sur 3

KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients

Paul Joseph Dyson, Christian Hartinger, Michael Groessl

2008

In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands

Paul Joseph Dyson, Christian Hartinger, Alexey Nazarov, Olivier Pierre Zava, Michael Groessl, Frédéric Schmitt, Muhammad Hanif

2008